NOVEL THERAPIES FOR MITOCHONDRIAL DYSFUNCTION PLUS, ELAMPIPRETIDE DISCUSSED: BOSTON, May 13, 2020 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Reenie McCarthy, CEO, will present at the UBS Virtual Global Healthcare Conference on Tuesday, May […]
Click here to view original web page at www.streetinsider.com